401 related articles for article (PubMed ID: 16555432)
1. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros A; Gahres N
Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
[No Abstract] [Full Text] [Related]
2. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib in multiple myeloma.
Vandenbroucke JP; Kroep JR
N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
[No Abstract] [Full Text] [Related]
5. Evolving role of novel agents for maintenance therapy in myeloma.
Magarotto V; Palumbo A
Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
[TBL] [Abstract][Full Text] [Related]
6. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
Prince HM; Schenkel B; Mileshkin L
Leukemia; 2007 Apr; 21(4):818-20; author reply 821. PubMed ID: 17301817
[No Abstract] [Full Text] [Related]
7. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
8. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
[TBL] [Abstract][Full Text] [Related]
11. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
12. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition in multiple myeloma.
Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
Lee SJ; Richardson PG; Sonneveld P; Schuster MW; Irwin D; San Miguel JF; Crawford B; Massaro J; Dhawan R; Gupta S; Anderson KC
Br J Haematol; 2008 Nov; 143(4):511-9. PubMed ID: 18986387
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
16. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Greipp P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
[TBL] [Abstract][Full Text] [Related]
17. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
[TBL] [Abstract][Full Text] [Related]
18. Clinical management of myeloma--state of the art.
Harousseau JL
Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib in multiple myeloma.
Cecchi M; Caccese E; Messori A
N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16177258
[No Abstract] [Full Text] [Related]
20. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Bladé J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine DL; Anderson KC; Harousseau JL
Br J Haematol; 2008 Oct; 143(2):222-9. PubMed ID: 18713253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]